Callidus Biopharma Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$15M
Callidus Biopharma General Information
Description
Developer of enzyme-replacement therapies for lysosomal-storage disorders. The company is focused on drug discovery, using a novel technology platform that attaches a form of the naturally occurring Insulin-like Growth Factor (IGF-2) to enhance the targeting of the therapeutic enzymes to relevant cells in the body.
Contact Information
Website
www.callidusbiopharma.comCorporate Office
- 3805 Old Easton Road
- Doylestown, PA 18902
- United States
Corporate Office
- 3805 Old Easton Road
- Doylestown, PA 18902
- United States
Callidus Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 21-Nov-2013 | $15M | Completed | Pre-Clinical Trials | ||
| 1. Early Stage VC (Series A) | 12-Apr-2013 | Completed | Pre-Clinical Trials |
Callidus Biopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Callidus Biopharma Patents
Callidus Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2014082080-A2 | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases | Inactive | 26-Nov-2012 | ||
| WO-2014082080-A3 | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases | Inactive | 26-Nov-2012 | ||
| WO-2012166653-A3 | Methods for coupling targeting peptides onto recombinant lysosomal enzymes | Inactive | 27-May-2011 | ||
| WO-2012166653-A2 | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases | Inactive | 27-May-2011 | ||
| WO-2012071422-A2 | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins | Inactive | 22-Nov-2010 | C07K14/47 |
Callidus Biopharma Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 120 Capital | Venture Capital | Minority | ||
| WuXi Healthcare Ventures | Corporate Venture Capital | Minority |
Callidus Biopharma FAQs
-
When was Callidus Biopharma founded?
Callidus Biopharma was founded in 2010.
-
Where is Callidus Biopharma headquartered?
Callidus Biopharma is headquartered in Doylestown, PA.
-
What industry is Callidus Biopharma in?
Callidus Biopharma’s primary industry is Drug Delivery.
-
Is Callidus Biopharma a private or public company?
Callidus Biopharma is a Private company.
-
What is the current valuation of Callidus Biopharma?
The current valuation of Callidus Biopharma is .
-
What is Callidus Biopharma’s current revenue?
The current revenue for Callidus Biopharma is .
-
How much funding has Callidus Biopharma raised over time?
Callidus Biopharma has raised $4.61M.
-
Who are Callidus Biopharma’s investors?
120 Capital and WuXi Healthcare Ventures have invested in Callidus Biopharma.
-
When was Callidus Biopharma acquired?
Callidus Biopharma was acquired on 21-Nov-2013.
-
Who acquired Callidus Biopharma?
Callidus Biopharma was acquired by Amicus Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process